title: Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg-1.
abstract: The pharmacokinetics of teicoplanin were investigated in 13 subjects with various degrees of renal impairment using a randomized two-period crossover design; 11 subjects completed both periods. Doses of 3 and 30 mg kg-1 were administered as single dose, 60-min constant rate intravenous infusions. Blood samples were obtained over 28 days and urine was collected over 48 h. Serum and urine were analyzed using a microbiological assay. As previously observed in studies conducted in renally impaired subjects, teicoplanin total and renal clearance significantly decreased with decreasing creatinine clearance (p < 0.0001). However, for these parameters, no differences between doses were observed. Dosage adjustment guidelines for renally impaired patients are usually developed using the ratio of total clearance in renally impaired patients to the total clearance in patients with normal renal function. Since no dose-related differences existed in the relationship between teicoplanin total clearance and creatinine clearance, initial dosage adjustment guidelines for renally impaired patients developed at 3 or 30 mg kg-1 are applicable over the range of 3 to 30 mg kg-1.
authors.affiliation: Marion Merrell Dow Inc., Cincinnati, OH 45215.
authors.forename: J A
authors.initials: JA
authors.lastname: Smithers
authors.forename: G A
authors.initials: GA
authors.lastname: Thompson
authors.forename: M T
authors.initials: MT
authors.lastname: Kenny
authors.forename: J K
authors.initials: JK
authors.lastname: Dulworth
authors.forename: H K
authors.initials: HK
authors.lastname: Kulmala
authors.forename: E W
authors.initials: EW
authors.lastname: Lewis
authors.forename: S J
authors.initials: SJ
authors.lastname: Ruberg
authors.forename: B E
authors.initials: BE
authors.lastname: Shapiro
authors.forename: W F
authors.initials: WF
authors.lastname: Keane
authors.forename: C E
authors.initials: CE
authors.lastname: Halstenson
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D017334:Teicoplanin / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D017334:Teicoplanin